Chronic Brain InjuryQualBotoxCovNCT05435404
Qualitative Study Patient & Physician Experiences Botox COVID-19
An observational study of Chronic Brain Injury and Cerebral Stroke, run by East Kent Hospitals University NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
During the COVID-19 pandemic and subsequent series of Lockdowns, clinic out-patient spasticity services were replaced with video based tele-consultation appointments, in order to reduce the potential risk of virus transmission between patients and clinicians in either direction. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Brain Injury, Cerebral Stroke, MS (Multiple Sclerosis)
- How many people
- 11 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 8 Oct 2021to 30 Apr 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: People with a diagnosis of severe muscle spasticity related to a neurological condition, who require treatment with Botulinum Toxin injection by a Consultant Physician and who are usually seen in Out-patient clinics in East Kent.
Who may be able to join
- Adults aged 18 and over with a diagnosis of severe spasticity, who are recommended to have Botulinum Toxin injection treatment in East Kent Hospital University NHS Foundation Trust (EKHUFT) Out-patient clinics.
Who cannot join
- Adults aged 18 and over who do not have a diagnosis of severe muscle spasticity that requires treatment with Botulinum Toxin injection.
- Adults unable to provide informed consent
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
East Kent Hospitals University NHS Trust
Canterbury, Kent, CT1 3NG
About this study
Official title: A Qualitative Research Study Into Patient, Carer and Physician Experiences of Spasticity Management Via Botulinum Toxin Treatment During and Post COVID-19 Pandemic. Perceptions, Opportunities and Barriers
During the COVID-19 pandemic and subsequent series of Lockdowns, clinic out-patient spasticity services were replaced with video based tele-consultation appointments, in order to reduce the potential risk of virus transmission between patients and clinicians in either direction. This meant that for an extensive period of time, this treatment could not be offered, and like many other specialist services, this resulted in a backlog of case referrals and an extensive clinic waiting list, where patient appointments and referrals were delayed by the pandemic.
There have been discussions in many professional network forums that have suggested that the necessary changes to appointments during the pandemic may have contributed to a build-up of pain and disability for patients who were unable to access spasticity management treatment when they needed it.
Read more
This research aims to gain insight and understanding of the individual experiences and perceptions of patients, carers and a physician who have been involved in spasticity treatment out-patient service clinics during and post COVID 19 pandemic. To do this, a qualitative research approach has been adopted and a group of 10 potential participants along with one consultant physician will be invited to participate in the study.
Participants will be provided with information on the research (Participant Information Sheet) and asked to provide written informed consent (Consent Form) in order to take part.
After providing consent, the participant will be interviewed via telephone. Data will be analysed using a thematic approach by the research team to identify the challenges, opportunities and barriers that may have been encountered during the pandemic and post pandemic period. All participants will be provided with a debrief document.
Read the detailed description
The idea for this study came out of a shared online discussion between healthcare professionals, managers and the Principal Investigator during the last 18 months of the COVID-19 Pandemic period.
Aims and Objectives:
- To explore the different perceptions of risks associated with attending an Out-patient appointment for BoNT injection treatment by patients, carers and medical doctors, who routinely use BoNT for spasticity management.
- To identify potential barriers, which may be physical and/or psychological which influence choice and decision making by patients and doctors
- To gain insight and understanding of potential perceived harms versus benefits regarding treatment decision making process from different perspectives (patients and doctors)
- To gain insight and understanding of how attitudes and behaviours may have changed now because of COVID-19
- To invite consideration of how identified barriers might potentially be overcome.
- To invite ideas and perspectives on whether the development of a video-based spasticity assessment measurement tool could be of potential benefit in this regard.
- To generate research knowledge on the above via Thematic Analysis of the data which will enable insight and understanding of key issues identified.
- To create and support opportunities to share the research knowledge generated in this study with professional networks and neuro-rehabilitation communities throughout the UK and globally via research presentation events and publications.
- To enable the potential for clinical service improvement with the consideration of the research knowledge outputs generated by this project.
- To help create and support the building a research participant database for further relevant research in the future
Deliverable research outputs
Research knowledge on the perceptions, opportunities and barriers experienced by patients, carers and physician in relation to spasticity management treatment with Botulinum Toxin injection during and post COVID-19.
Research knowledge on the factors which influence patients', carers' and physician's individual perceptions of the risk versus benefit appraisal with regard to attending an Out-patient spasticity clinic.
Research knowledge on what potential strategies might help support and encourage patients in terms of communication and understanding of spasticity management
Research knowledge which establishes an evidence base of individual patient, carer and Physician experiences, which can inform the development of best practice guidelines for spasticity management and contribute to the design of a potential protocol to identify how patients could be prioritised for this type of treatment during any future pandemic.
Methodology.
The investigators have adopted a qualitative approach in order to enable in-depth insight and understanding to be gained from individual participants in order to understand participants' own experiences and perspectives (9). The theoretical framework used is based on the adoption of the constructivist paradigm, where it is understood that there are multiple realities, experienced by individuals, which are all equally valid and carry meaning for the individual. The investigators will use Thematic Analysis to organise and code the data and to enable us to develop emergent themes based on an inductive approach (10).
Methods. Sampling and recruitment. A purposive sample of participants will be invited to take part. These potential participants will be identified by the research team and will comprise patients, who have attended Dr Sakel's Out-patient spasticity clinics over the last 18 months. These clinics will include both video based and in person face to face clinics.
Potential participants will meet the following eligibility criteria:
- Adults aged 18 and over
- A diagnosis of severe spasticity who are recommended to have Botulinum Toxin injection treatment in East Kent Hospital University NHS Foundation Trust (EKHUFT) Out-patient clinics.
The investigators will aim to recruit a sample of 10 potential participants (patients and carers) and 1 Physician injector.
Study design and setting. Qualitative design with semi-structured interviews conducted by the co-investigator by telephone. Interviews will be audio-recorded and transcribed by the co-investigator. An interview topic guide will be used to support the structure of the interviews.
Interviews will be scheduled with eligible participants at mutually convenient dates and times.
It is anticipated that the length of preliminary interviews will vary depending on the individual. Participants may be interviewed on a number of occasions at mutually convenient times to enable in depth data gathering.
Schedule of research project time-line. Submission of protocol and documents for Ethical Approval via IRAS and HRA - September 2021 When approval is received, the team will start recruitment and the research. Recruitment of participants and interviews to be completed by mid-December 2021.
Data analysis will be conducted from 01/03/2022 to 01/04/2022. Preparation of report and abstract for potential conference submission by 30/04/2022.
- Keywords
- spasticity, botulinum toxin, qualitative research, rehabilitation
- Medical subject headings
- Brain Injury, Chronic, Stroke, Multiple Sclerosis, Muscle Spasticity
What is being measured
The primary outcome is the main question the study is designed to answer.
Interview with participant
Telephone interview between member of research team and participant
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jun 2022
- Study start8 Oct 2021
- Primary completion30 Apr 2022
- Study completion30 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Brain InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- East Kent Hospitals University NHS Foundation Trust
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Mohamed Dr Sakel, MBBS, Principal investigator, East Kent Hospitals University NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05435404
- Sponsor's protocol ID
- EastKHT
- Acronym
- QualBotoxCov
- Status last verified
- Jun 2022
- First submitted
- 5 Oct 2021
- Last updated
- 28 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: None to be shared
Publications
Sakel M, Saunders K, Faruqui R, Keene J, Wilkinson D. Living With Spasticity During the COVID-19 Pandemic: A Qualitative Study of Patient, Carer and Physician Experiences. Health Expect. 2024 Oct;27(5):e70032. doi: 10.1111/hex.70032.
PubMed 39311542
Study at a glance
From the registry record, last updated by the sponsor on 28 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Qualitative Research Study Into Patient, Carer and Physician Experiences of Spasticity Management Via Botulinum Toxin Treatment During and Post COVID-19 Pandemic. Perceptions, Opportunities and Barriers
- ClinicalTrials.gov ID
- NCT05435404
- Acronym / sponsor ID
- QualBotoxCov / EastKHT
- Keywords
- spasticity, botulinum toxin, qualitative research, rehabilitation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- East Kent Hospitals University NHS Foundation TrustOther government
- Study start
- 8 Oct 2021 (actual)
- Primary completion
- 30 Apr 2022 (actual)
- Study completion
- 30 Apr 2022 (actual)
- First posted
- 28 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
During the COVID-19 pandemic and subsequent series of Lockdowns, clinic out-patient spasticity services were replaced with video based tele-consultation appointments, in order to reduce the potential risk of virus transmission between patients and clinicians in either direction. This meant that for an extensive period of time, this treatment could not be offered, and like many other specialist services, this resulted in a backlog of case referrals and an extensive clinic waiting list, where patient appointments and referrals were delayed by the pandemic.
There have been discussions in many professional network forums that have suggested that the necessary changes to appointments during the pandemic may have contributed to a build-up of pain and disability for patients who were unable to access spasticity management treatment when they needed it.
This research aims to gain insight and understanding of the individual experiences and perceptions of patients, carers and a physician who have been involved in spasticity treatment out-patient service clinics during and post COVID 19 pandemic. To do this, a qualitative research approach has been adopted and a group of 10 potential participants along with one consultant physician will be invited to participate in the study.
Participants will be provided with information on the research (Participant Information Sheet) and asked to provide written informed consent (Consent Form) in order to take part.
After providing consent, the participant will be interviewed via telephone. Data will be analysed using a thematic approach by the research team to identify the challenges, opportunities and barriers that may have been encountered during the pandemic and post pandemic period. All participants will be provided with a debrief document.
Detailed description
The idea for this study came out of a shared online discussion between healthcare professionals, managers and the Principal Investigator during the last 18 months of the COVID-19 Pandemic period.
Aims and Objectives:
- To explore the different perceptions of risks associated with attending an Out-patient appointment for BoNT injection treatment by patients, carers and medical doctors, who routinely use BoNT for spasticity management.
- To identify potential barriers, which may be physical and/or psychological which influence choice and decision making by patients and doctors
- To gain insight and understanding of potential perceived harms versus benefits regarding treatment decision making process from different perspectives (patients and doctors)
- To gain insight and understanding of how attitudes and behaviours may have changed now because of COVID-19
- To invite consideration of how identified barriers might potentially be overcome.
- To invite ideas and perspectives on whether the development of a video-based spasticity assessment measurement tool could be of potential benefit in this regard.
- To generate research knowledge on the above via Thematic Analysis of the data which will enable insight and understanding of key issues identified.
- To create and support opportunities to share the research knowledge generated in this study with professional networks and neuro-rehabilitation communities throughout the UK and globally via research presentation events and publications.
- To enable the potential for clinical service improvement with the consideration of the research knowledge outputs generated by this project.
- To help create and support the building a research participant database for further relevant research in the future
Deliverable research outputs
Research knowledge on the perceptions, opportunities and barriers experienced by patients, carers and physician in relation to spasticity management treatment with Botulinum Toxin injection during and post COVID-19.
Research knowledge on the factors which influence patients', carers' and physician's individual perceptions of the risk versus benefit appraisal with regard to attending an Out-patient spasticity clinic.
Research knowledge on what potential strategies might help support and encourage patients in terms of communication and understanding of spasticity management
Research knowledge which establishes an evidence base of individual patient, carer and Physician experiences, which can inform the development of best practice guidelines for spasticity management and contribute to the design of a potential protocol to identify how patients could be prioritised for this type of treatment during any future pandemic.
Methodology.
The investigators have adopted a qualitative approach in order to enable in-depth insight and understanding to be gained from individual participants in order to understand participants' own experiences and perspectives (9). The theoretical framework used is based on the adoption of the constructivist paradigm, where it is understood that there are multiple realities, experienced by individuals, which are all equally valid and carry meaning for the individual. The investigators will use Thematic Analysis to organise and code the data and to enable us to develop emergent themes based on an inductive approach (10).
Methods. Sampling and recruitment. A purposive sample of participants will be invited to take part. These potential participants will be identified by the research team and will comprise patients, who have attended Dr Sakel's Out-patient spasticity clinics over the last 18 months. These clinics will include both video based and in person face to face clinics.
Potential participants will meet the following eligibility criteria:
- Adults aged 18 and over
- A diagnosis of severe spasticity who are recommended to have Botulinum Toxin injection treatment in East Kent Hospital University NHS Foundation Trust (EKHUFT) Out-patient clinics.
The investigators will aim to recruit a sample of 10 potential participants (patients and carers) and 1 Physician injector.
Study design and setting. Qualitative design with semi-structured interviews conducted by the co-investigator by telephone. Interviews will be audio-recorded and transcribed by the co-investigator. An interview topic guide will be used to support the structure of the interviews.
Interviews will be scheduled with eligible participants at mutually convenient dates and times.
It is anticipated that the length of preliminary interviews will vary depending on the individual. Participants may be interviewed on a number of occasions at mutually convenient times to enable in depth data gathering.
Schedule of research project time-line. Submission of protocol and documents for Ethical Approval via IRAS and HRA - September 2021 When approval is received, the team will start recruitment and the research. Recruitment of participants and interviews to be completed by mid-December 2021.
Data analysis will be conducted from 01/03/2022 to 01/04/2022. Preparation of report and abstract for potential conference submission by 30/04/2022.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- People with a diagnosis of severe muscle spasticity related to a neurological condition, who require treatment with Botulinum Toxin injection by a Consultant Physician and who are usually seen in Out-patient clinics in East Kent.
Key inclusion criteria (1 listed)
- Adults aged 18 and over with a diagnosis of severe spasticity, who are recommended to have Botulinum Toxin injection treatment in East Kent Hospital University NHS Foundation Trust (EKHUFT) Out-patient clinics.
Key exclusion criteria (2 listed)
- Adults aged 18 and over who do not have a diagnosis of severe muscle spasticity that requires treatment with Botulinum Toxin injection.
- Adults unable to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Interview with participant
Time frame: 1 month
Telephone interview between member of research team and participant
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jun 2022.
- Derived from this study: PubMed 39311542Sakel M, Saunders K, Faruqui R, Keene J, Wilkinson D. Living With Spasticity During the COVID-19 Pandemic: A Qualitative Study of Patient, Carer and Physician Experiences. Health Expect. 2024 Oct;27(5):e70032. doi: 10.1111/hex.70032.
- Individual participant dataSharing planned: No. None to be shared
Related trials for Chronic Brain Injury
Recruiting
Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
Cerebral Palsy, Muscular Dystrophy
RecruitingObservational study
Study of Sagittal Pelvic Statics in the Sitting Position in Children With Cerebral Palsy
Cerebral Palsy Infantile
Not yet recruitingObservational study
Turkish Translation, Cross-Cultural Adaptation, Validity, and Reliability of the ABILHAND-Kids Young CP Scale
Cerebral Palsy
Not yet recruiting
Ayres Sensory Integration Intervention for Children With Cerebral Palsy
Cerebral Palsy (CP)
RecruitingObservational study
Functional Benefits of Multisite Upper Limb Surgery in Children With Unilateral Cerebral Palsy (RETRO-CHIRc)
Cerebral Palsy, Hemiplegia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed Dr Sakel, MBBS principal investigator
East Kent Hospitals University NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Brain Injury and Cerebral Stroke, run by East Kent Hospitals University NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interview with participant (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05435404, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2022.